About Us
TAKE A NEW LEAP FORWARD WITH
INNOVATION TECHNOLOGY
2024
| 2024.03 | MOU with Dongkook pharmaceutical on ‘AI-driven advanced pharmaceutical development’ |
| 2024.01 | Selected as ‘AI-driven Bio data-based leading technology development project by MIST’ |
| MOU with HLB bioStep on ‘AI drug discovery platform development’ | 2023.12 |
| Joint research with SAMJIN PHARM on ‘AI-based innovative drug development’ | 2023.10 |
| Selected as ‘Innovative future medical research center by MSIT’ | 2023.05 |
| MOU with KMEDI Hub on ‘AI-based patient-customized NCE development’ | 2023.05 |
| MOU with FUTURE MEDICINE on ‘AI-Nucleoside NCE platform development’ | 2023.05 |
| Presentation of ‘anti-CAF candidates & mechanism’ research results at AACR 2023 | 2023.04 |
| MOU with NEX-I on ‘AI-based new antibody drug development’ | 2023.03 |
2023
2022
| 2022.10 | Launch of AD3 |
| 2022.10 | MOU with SMC on ‘AI-based new drug & RNA cancer vaccine development’ |
| 2022.09 | Selected as ‘industry-University linked new drug development support project by MSIT’ |
| 2022.06 | Selected as ‘AI-based innovative new drug discovery project by MIST’ |
| Series-B investment | 2021.12 |
| Joint research with NEURACLE SCIENCE on ‘AI-based innovative drug development’ | 2021.12 |
| Selected as ‘2021 National new drug development project by MOHW’ | 2021.11 |
| Selected as ‘Digital pathology AI solution development project by MOHW’ | 2021.04 |
2021
2020
| 2020.11 | Series-A investment |
| 2020.01 | Joint research with Yonsei University Health System on ‘anti-diabetes drug development’ |
| Joint research with KRICT on ‘anti-cancer drug development’ | 2019.12 |
| Selected as ‘2019 AI drug development platform project by MSIT’ | 2019.05 |
2019
2018
| 2018.10 | Company’s name changed to Arontier |
| 2018.02 | R&D Center founded |
| FURAME founded | 2017.11 |
2017
2024
| 2024.03 | MOU with Dongkook pharmaceutical on ‘AI-driven advanced pharmaceutical development’ |
| 2024.01 | Selected as ‘AI-driven Bio data-based leading technology development project by MIST’ |
2023
| 2023.12 | MOU with HLB bioStep on ‘AI drug discovery platform development’ |
| 2023.10 | Joint research with SAMJIN PHARM on ‘AI-based innovative drug development’ |
| 2023.05 | Selected as ‘Innovative future medical research center by MSIT’ |
| 2023.05 | MOU with KMEDI Hub on ‘AI-based patient-customized NCE development’ |
| 2023.05 | MOU with FUTURE MEDICINE on ‘AI-Nucleoside NCE platform development’ |
| 2023.04 | Presentation of ‘anti-CAF candidates & mechanism’ research results at AACR 2023 |
| 2023.03 | MOU with NEX-I on ‘AI-based new antibody drug development’ |
2022
| 2022.10 | Launch of AD3 |
| 2022.10 | MOU with SMC on ‘AI-based new drug & RNA cancer vaccine development’ |
| 2022.09 | Selected as ‘Industry-University linked new drug development support project by MSIT’ |
| 2022.06 | Selected as ‘AI-based innovative new drug discovery project by MSIT’ |
2021
| 2021.12 | Series-B investment |
| 2021.12 | Joint research with NEURACLE SCIENCE on ‘AI-based innovative drug development’ |
| 2021.11 | Selected as ‘2021 National new drug development project by MOHW’ |
| 2021.04 | Selected as ‘Digital pathology AI solution development project by MOHW’ |
2020
| 2020.11 | Series-A investment |
| 2020.01 | Joint research with Yonsei University Health System on ‘anti-diabetes drug development’ |
2019
| 2019.12 | Joint research with KRICT on ‘anti-cancer drug development’ |
| 2019.05 | Selected as ‘2019 AI drug development platform project by MSIT’ |
2018
| 2018.10 | Company’s name changed to Arontier |
| 2018.02 | R&D Center founded |
2017
| 2017.11 | FURAME founded |
ARONTIER TEL: +82-2-597-0365 | FAX: +82-2-587-0365 | Email: arontier@arontier.co
ARONTIER TEL: +82-2-597-0365
FAX: +82-2-587-0365
Email: arontier@arontier.co
ADDRESS : 15F, 241, Gangnam-daero, Seocho-gu, Seoul, Republic of Korea
Copyright 2018~2021 ARONTIER. All Rights Reserved.